Why the Recce (ASX:RCE) share price is racing 5% higher today

This ASX share is off to a flying start this week…

| More on:
A medical researcher in a white coat holds laboratory equipment and smiles.

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on the move today. It comes after the pharmaceutical company provided a patent update on its synthetic anti-infectives.

At the time of writing, the Recce share price is up 5.73% to $1.015. In comparison, the All Ordinaries Index (ASX: XAO) is down 0.65% to 7,238 points.

What's pushing the Recce share price higher?

The Recce share price is pushing higher today after the Chinese Patent Office granted Patent Family 3 to Recce anti-infectives. Titled 'Anti-virus Agent and Method for Treatment of Viral Infection', the patent allows marketing and manufacturing monopolies until February 2037.

According to the company's update, the granted claims relate to antibiotic drug Recce 327 and the new anti-viral formulation Recce 529.

China is considered one of the largest pharmaceutical markets in the world, valued at roughly US$86.74 billion. This places the lucrative Chinese market behind the United States and Japan in terms of revenue size.

The latest patent approval in Family 3 follows recent patent grants in Europe and Japan.

The country witnesses millions of cases where infections are caused by lipid enveloped or coated viruses. Patent Family 3 applications in other major pharmaceutical markets around the world are in their own advanced stages of independent patent reviews.

Recce CEO James Graham commented:

Recce's intellectual property portfolio continues to grow in line with our business strategy and the unprecedented global infectious disease crisis before us. With this new patent granted in one of the largest pharmaceutical markets in the world, our market monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.

About the Recce share price

Recce is involved in the advancement of synthetic antibodies designed to address the global health challenge of antibiotic-resistant superbugs. The medical company's flagship drug Recce 327 is being developed to treat blood infections and sepsis.

The group operates solely in research and development in both Australia and the United States.

The Recce share price has fallen by more than 25% in the past 12 months and 3.3% year-to-date. The company's shares hit a 52-week low of 86 cents in late June after weak investor sentiment kicked in.

At today's price, Recce commands a market capitalisation of around $177 million, with roughly 173.7 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman with a scared look has hands on her face.
Broker Notes

Bapcor shares fell more than 30% yesterday. Should investors buy in the dip?

Is this a value opportunity?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Broker Notes

Broker raises price targets on 2 ASX 200 shares to buy

Ord Minnett has just upped its 12-month share price targets on 2 buy-rated ASX 200 stocks.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why DroneShield, Gentrack, Metals X, and Northern Star shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Morgans says these ASX can rise 30% to 50%

The broker has good things to say about these shares.

Read more »

Two businessmen look out at the city from the top of a tall building.
Broker Notes

2 ASX REITs to buy in July: expert

Is it time to consider ASX REITs?

Read more »